Evidence map›Paper›PMID 41928274›Full record

ReviewCell communication and signaling : CCS2026

Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses.

Jiaming Cui, Jingru Han, Yang Dai, Shengqiang Li, Xinyu Wang, Ting Ge, Guixin He, Juyue Zhou, Li Yang, Yuanyuan Tian and 5 more

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jiaming Cui *Central Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Jingru Han *School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yang DaiRehabilitation Department, Jiangjin Hospital Affiliated with, Chongqing University of Traditional Chinese Medicine, Chongqing, China.
Shengqiang LiNational Clinical Research Center for Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xinyu WangNational Clinical Research Center for Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Ting GeCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Guixin HeCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Juyue ZhouCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Li YangCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yuanyuan TianCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yingying XieCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Lefan LiuCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Jinghui DuNational Clinical Research Center for Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. djh4321@126.com.
Wentao LiNational Clinical Research Center for Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. v23liwentao@163.com.
Jianchun YuCentral Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. yujianchun2000@163.com.

Funding

the National Clinical Research Center for Acupuncture and Moxibustion and the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine NCRCOP2024018; JYTC2025015
6 · The paper itself

Abstract

The efficacy of antitumor immune responses depends not only on the activation and effector function of local immune cells but also on the dynamic interplay between the tumor microenvironment and systemic immunity. Emerging evidence indicates that the migration of immune cells from tumor sites to secondary lymphoid organs and the circulatory system is essential for translating localized immune activity into systemic protective responses. This migratory process displays marked organ-specific spatial heterogeneity and temporal variability, which complicate the prediction and modulation of systemic outcomes through local therapeutic strategies.We propose the concept of Organ-Specific Migration Licensing (OSML) to delineate the mechanisms and biological underpinnings that govern immune cell trafficking in tumor immunity. This framework integrates spatial heterogeneity, temporal dynamics, and intervention-induced reprogramming to clarify how organ-specific factors shape immune efficacy and resistance. Crucially, these three dimensions are not independent but intricately coupled, forming a dynamic regulatory system that determines whether immune cells receive “migration permission”. The OSML paradigm advances tumor immunotherapy from a focus on local modulation to one of systemic coordination, offering a conceptual and practical foundation for optimizing organ-targeted combination therapies.

Indexed as

Cell MovementNeoplasmsOrgan SpecificityAnimalsHumansTumor MicroenvironmentImmune cell migrationMicroenvironmentOrgan-Specific Migration LicensingSpatial heterogeneitySystemic immunityTemporal dynamicsTumor immunity

Identifiers

PMID41928274
PMCPMC13169691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.